Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 11/20 | 0.58 |
| ▸ | PGR | P06401 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | GHSR | Q92847 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4123404 | 0.87 | AR (0.64) | ARPGRCYP3A4GRM4CNR2 | |
| SCHEMBL9891509 | 0.85 | AR (0.63) | ARPGRCYP3A4GRM4CNR2 | |
| SCHEMBL8029788 | 0.82 | AR (0.60) | ARPGRCYP3A4GRM4CNR2 | |
| SCHEMBL8530877 | 0.82 | AR (0.58) | ARPGRCYP3A4GRM4CYP2C19 | |
| SCHEMBL9891902 | 0.81 | AR (0.64) | ARCYP3A4GRM4CYP2C19ABCB11 | |
| SCHEMBL4137272 | 0.81 | AR (0.74) | ARPGR | |
| SCHEMBL4137264 | 0.81 | AR (0.74) | ARPGR | |
| SCHEMBL8410375 | 0.80 | AR (0.79) | ARPGRCYP3A4CYP2C19ABCB11 | |
| SCHEMBL13695983 | 0.79 | AR (0.54) | AR | |
| SCHEMBL463590 | 0.79 | AR (0.62) | ARGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090226368-A1 | Androgen-Receptor (AR) Ligands for Use in the Treatment and Diagnosis of AR-Related Pathologies | MEDICAL RESEARCH FUND AT THE TEL AVIV SOURASKY MEDICAL CENTER (IL) | 2009-09-10 | — | — | US | disclosed |
| EP-1957059-A1 | ANDROGEN-RECEPTOR (AR) LIGANDS FOR USE IN THE TREATMENT AND DIAGNOSIS OF AR-RELATED PATHOLOGIES | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007057909-A1 | ANDROGEN-RECEPTOR (AR) LIGANDS FOR USE IN THE TREATMENT AND DIAGNOSIS OF AR-RELATED PATHOLOGIES | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD. (IL) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226368-A1 | Androgen-Receptor (AR) Ligands for Use in the Treatment and Diagnosis of AR-Related Pathologies | AR, SHBG, ESRRB | AR 1/4885PGR 10/4885CYP3A4 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.